Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, was evaluated in a pooled analysis involving 2356 high cardiovascular risk patients.
Obicetrapib significantly reduced LDL cholesterol (by 37%) and apolipoprotein B (by 21%), alongside a notable 37% reduction in lipoprotein(a) levels.
Absolute reductions in Lp(a) were comparable in patients with moderate versus high baseline Lp(a) levels, highlighting its potential utility across a spectrum of elevations.
This lipid-lowering profile positions obicetrapib as a promising therapeutic for patients not typically qualifying for RNA-based Lp(a)-lowering therapies.
